Skip to content

Study · Randomized controlled trial · n = 73 · 1990

2 results

Nafarelin in the treatment of pelvic pain caused by endometriosis.

Shaw RW

American journal of obstetrics and gynecology1 Feb 1990Cited by 20 (Europe PMC)

PMID2137972 (opens in a new tab)DOI10.1016/0002-9378(90)90433-8 (opens in a new tab)PepBankPUB-02137972
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Among symptomatic endometriosis patients, improvement occurred in 94% with nafarelin and 91% with danazol.

    In plain wordsAmong symptomatic endometriosis patients, 94% improved with nafarelin compared with 91% with danazol.

    Peptide
    Nafarelin
    Outcome
    IncreaseSubjective symptom improvement
    Study

    n = 73

    Comparator
    Danazol
    Outcome group
    Pain · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Measurements

    Symptom improvement
    94%
    nafarelin
    Symptom improvement
    91%
    danazol

    Source sentences

    Summary
    Among 73 patients who had subjective symptoms (dysmenorrhea, dyspareunia, or pelvic pain) at baseline, 94% of patients treated with nafarelin and 91% of those treated with danazol had improvement.
    1 context sentence
    Summary · context
    As part of a large, multicenter trial, 82 patients with endometriosis were randomized to 6 months of treatment with either nafarelin or danazol.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with endometriosis, physical findings resolved in similar percentages with nafarelin and danazol.

    In plain wordsIn patients with endometriosis, nafarelin and danazol had similar rates of resolution of physical findings.

    Peptide
    Nafarelin
    Outcome
    Direction not reportedResolution of physical findings
    Study

    n: not reported in source

    Comparator
    Danazol
    Outcome group
    Organ injury · Reproductive and sexual health
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Resolution of physical findings also was observed in similar percentages of patients in each treatment group.
    1 context sentence
    Summary · context
    As part of a large, multicenter trial, 82 patients with endometriosis were randomized to 6 months of treatment with either nafarelin or danazol.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.